Albuterol-budesonide combo lowered risk of a severe asthma exacerbation: NEJM
A new study published in The New England Journal of Medicine showed that the participants with asthma who remained uncontrolled despite therapy were less likely to experience a severe asthma exacerbation when albuterol–budesonide was used as required than when albuterol was used alone.
In individuals with moderate-to-severe asthma, as-needed use of albuterol–budesonide has been demonstrated to significantly reduce the likelihood of a severe asthma exacerbation compared to as-needed use of albuterol alone. Under the trade name Airsupra®, albuterol/budesonide is an authorized inhaled corticosteroid (ICS) and short-acting beta2-agonist (SABA) asthma rescue medication.
The patients with asthma who are 18 years of age or older can use the medication to prevent or treat bronchoconstriction as needed and to lower their risk of exacerbations. There is a need for information on albuterol-budesonide in mild asthma. Thus, Craig LaForce and colleagues carried out this investigation to examine the effectiveness of using albuterol/budesonide as needed for moderate asthma.
Those aged 12 and older who had uncontrolled mild asthma despite using SABA and/or low-dose inhaled glucocorticoids or leukotriene-receptor antagonists were the subjects of a completely virtual, multicenter study. For a maximum of 52 weeks, the participants were randomized 1:1 to receive either albuterol (180 μg) + budesonide (160 μg) or albuterol alone (180 μg), administered as two inhaler actuations each dosage.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.